Genetically engineered macrophages carrying an oncolytic adenovirus were developed to maintain an anti-tumoral-like phenotype and deliver interleukin-12 and CXCL9 directly to local tumor sites, thereby reversing the immunosuppressive TME [178]. The gene discussed is CXCL9; the disease is neoplasm.